Aurobindo Pharma a ranar alhamis ya ce an tsawaita wa'adin tattaunawa tsakanin bangaren CuraTeQ Biologics da Merck Sharp & Dohme Singapore don gudanar da ayyukan samar da kwangilar halittu har zuwa watan Mayu na shekara mai zuwa. A bara a cikin Oktoba, CuraTeQ Biologics Pvt Ltd da Merck Sharp & Dohme Singapore Trading Pte Ltd da abokan haɗin gwiwa (MSD) sun sanya hannu kan wasiƙar niyya (LoI) don ayyukan masana'antar kwangila (CMO) don nazarin halittu, ta yadda bangarorin suka yi niyya don kammala aikin. Tattaunawar har zuwa Maris 31, 2024.